A randomized double blind placebo controlled trial of zoledronate in the treatment of bone erosions in gout
Phase 2
Completed
- Conditions
- GoutMusculoskeletal - Other muscular and skeletal disorders
- Registration Number
- ACTRN12608000463370
- Lead Sponsor
- niversity of Auckland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
A diagnosis of gout, as described by Wallace.
At least one tophus, confirmed by a rheumatologist
On stable therapy for gout (no change in the last 3 months)
Age over 18 years
Able to provide informed consent
Exclusion Criteria
Prolonged treatment with potent bisphosphonates in the last two years
Impaired renal function (creatinine clearance <30 ml/minute)
Serum calcium < 2.1mmol/L
Serum 25(OH)D < 15ng/ml
Allergy to bisphosphonate
Pregnancy or breastfeeding
Unstable systemic medical condition
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in total erosion score as determined by computed tomography (CT)scanning of the feet[At baseline, 1 year and 2 years]
- Secondary Outcome Measures
Name Time Method